To See the Unseen® is the beginning of understanding

Vladimir Gurevich founded Fugent LLC in 1996 to inspire and enable healing discoveries. His vision was to enable the world’s pioneering researchers to “See the Unseen®” with gentle, reliable, and efficient products that could be made with minimal environmental impact. Vladimir’s first innovation, FuGENE®6 was one of the first transfection reagents to be sold by Roche and Promega and is still an industry leader for transfecting DNA into eukaryotic cells. Later, Vladimir discovered the first non-liposomal 100% synthetic DNA transfection reagent, FuGENE®HD. This product is being used today in various biotechnology applications, from the gentle interrogation of cellular action to the production of vaccines and medicines.


FuGENE® has continued to innovate and now offers a full portfolio of best-in-class transfection reagents that span applications across DNA, RNA and CRISPR/Cas9 delivery, into a wide range of biologically relevant cell lines.  We seek to meet the needs of researchers, scientists, and clinicians in delivering nucleic acids and proteins to cells at market-leading efficiencies while remaining gentle on cells.


The FuGENE® vision is to inspire healing discoveries and empower our customers to solve some of the world’s most challenging problems. By understanding the challenges facing scientists at the forefront of discovery, FuGENE® is working to identify and empower best-in-class solutions for our customers. For over 25 years FuGENE® has been striving to find these solutions by developing products that are gentle, reliable, and effective, so the world’s pioneering scientists have the best products possible to See the Unseen®.  From our first peer-reviewed publication in 1998, to our now thousands of peer-reviewed publications, we are here to make a true difference for our customers in aiding their innovative and life-saving research.